-
Mashup Score: 88
Summary:. PET imaging enables the spatiotemporal assessment of tumor biomarkers. In this issue, Kong and colleagues describe the clinical PET imaging of tumor-associated fibroblasts, which improved the diagnostic accuracy and management of a subset of patients with medullary thyroid carcinoma.See related article by Kong et al., p. 316
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 92Engineering cancer’s end: An interdisciplinary approach to confront the complexities of cancer - 1 year(s) ago
Cancer engineering is an interdisciplinary approach that promises to confront the complexities of cancer and accelerate transformative discoveries by integrating innovative fields across engineering and the physical sciences with a focus on cancer. We offer a conceptual framework for the hallmarks of cancer engineering, integrating 12 fields: system dynamics; imaging, radiation, and spectroscopy; robotics and controls; solid mechanics; fluid mechanics; chemistry and nanomaterials; mathematics and simulation; cellular and protein engineering; kinetics and thermodynamics; materials science; manufacturing and biofabrication; and microsystems.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
Biological approaches have led to numerous advances in #cancer but integrating fields across #engineering & the #physical sciences may accelerate cancer discovery & therapy. https://t.co/Xm2IEM85vk https://t.co/SqZATBIDqM
-
-
Mashup Score: 67Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions - 1 year(s) ago
AbstractArtificial intelligence (AI) in oncology is advancing beyond algorithm development to integration into clinical practice. This review describes the current state of the field, with a specific focus on clinical integration. AI applications are structured according to cancer type and clinical domain, focusing on the four most common cancers and tasks of detection, diagnosis, and treatment. These applications encompass various data modalities, including imaging, genomics, and medical records. We conclude with a summary of existing challenges, evolving solutions, and potential future directions for the field.Significance:. AI is increasingly being applied to all aspects of oncology, where several applications are maturing beyond research and development to direct clinical integration. This review summarizes the current state of the field through the lens of clinical translation along the clinical care continuum. Emerging areas are also highlighted, along with common challenges, evo
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
The potential role of AI in clinical practice for oncology is anchored around improving detection, diagnosis, and treatment. https://t.co/xhODvLFAOW https://t.co/9hSkrVtncE
-
-
Mashup Score: 66Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions - 1 year(s) ago
AbstractArtificial intelligence (AI) in oncology is advancing beyond algorithm development to integration into clinical practice. This review describes the current state of the field, with a specific focus on clinical integration. AI applications are structured according to cancer type and clinical domain, focusing on the four most common cancers and tasks of detection, diagnosis, and treatment. These applications encompass various data modalities, including imaging, genomics, and medical records. We conclude with a summary of existing challenges, evolving solutions, and potential future directions for the field.Significance:. AI is increasingly being applied to all aspects of oncology, where several applications are maturing beyond research and development to direct clinical integration. This review summarizes the current state of the field through the lens of clinical translation along the clinical care continuum. Emerging areas are also highlighted, along with common challenges, evo
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
The potential role of AI in clinical practice for oncology is anchored around improving detection, diagnosis, and treatment. https://t.co/xhODvLFAOW https://t.co/9hSkrVtncE
-
-
Mashup Score: 61Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions - 1 year(s) ago
AbstractArtificial intelligence (AI) in oncology is advancing beyond algorithm development to integration into clinical practice. This review describes the current state of the field, with a specific focus on clinical integration. AI applications are structured according to cancer type and clinical domain, focusing on the four most common cancers and tasks of detection, diagnosis, and treatment. These applications encompass various data modalities, including imaging, genomics, and medical records. We conclude with a summary of existing challenges, evolving solutions, and potential future directions for the field.Significance:. AI is increasingly being applied to all aspects of oncology, where several applications are maturing beyond research and development to direct clinical integration. This review summarizes the current state of the field through the lens of clinical translation along the clinical care continuum. Emerging areas are also highlighted, along with common challenges, evo
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
The potential role of AI in clinical practice for oncology is anchored around improving detection, diagnosis, and treatment. https://t.co/xhODvLFAOW https://t.co/9hSkrVtncE
-
-
Mashup Score: 4Are we entering a new era of cancer treatments? - 1 year(s) ago
Cancer patient survival rates are better than ever, but many cancers remain tough to treat. The current wave of innovations in science and technology could provide new answers. Learn why scientists are focusing on the unique biology of each patient and how Amgen is part of the movement. (Partner Content)
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet-
Cancer is not a uniform disease, & neither is its treatment. I share how #MyCompany pairs our biology-first approach with the latest technology to investigate targeted options for patients who need them most in this #AmgenSponsored article: https://t.co/ex834Sauvv https://t.co/t5D0ChHMEV
-
-
Mashup Score: 105Cancer Today - 1 year(s) ago
CANCER TODAY enables a comprehensive assessment of the cancer burden worldwide in 2022, based on the GLOBOCAN estimates of incidence, mortality and prevalence for year 2022 in 185 countries or territories for 36 cancer types by sex and age group.
Source: gco.iarc.frCategories: General Medicine News, Hem/OncsTweet-
WHO Global #Cancer Observatory just released it’s latest update. Explore incidence, mortality, & prevalence for 36 cancer types in 185 countries. You can also discover trends until 2050!. It is a fascinating website to explore. https://t.co/PC58e39YSX https://t.co/oFd207fZPE
-
-
Mashup Score: 15Next generation radiotheranostics promoting precision medicine - 2 year(s) ago
Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-DOTATATE for neuroendocrine tumors, and 177Lu-PSMA (prostate-specific membrane antigen) for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.
Source: www.annalsofoncology.orgCategories: General Medicine News, Oncologists1Tweet-
#Radioligands or radiotheranostics is a rapidly developing field in #cancer therapy, that has impacted thyroid, neuroendocrine, & prostate tumors. This review provides a good landscape view of this class of agents. https://t.co/yeygRQvFge https://t.co/BIokmdA85w
-
-
Mashup Score: 109Antibody–drug conjugates: in search of partners of choice - 2 year(s) ago
Antibody–drug conjugates (ADCs) have become a credentialled class of anticancer drugs for both solid and hematological malignancies, with regulatory a…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
After a prolific #ESMO23, ADC gained yet extra-visibility. But one of the key questions for the future of #ADC is what is their best partner of choice? https://t.co/CeGweoiW8a https://t.co/eejJBn4AZQ
-
-
Mashup Score: 9ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results - 2 year(s) ago
Nature Medicine – In the first stage of the BR.36 adaptive trial in patients with non-small cell lung cancer receiving anti-PD1 immunnotherapy, the primary endpoint of concordance between…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Patients with #ctDNA clearance post PD1 #immunotherapy have better PFS & OS in this prospective study. Liquid biopsies may be used to rapidly & accurately determine clinical response, especially in the metastatic setting. https://t.co/2eVcs3M7EJ https://t.co/fjXX9PYXLa
-
Seeing the unseen! FAP-PET unlocks TME visualization, allowing the imaging of cancer-associated fibroblasts (CAFs), notably in tumors with low metabolic activity. https://t.co/mEYlrp9Snl https://t.co/eFBrfcxwlt